Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metrika gets US nod for HbA1c test:

This article was originally published in Clinica

Executive Summary

Diagnostic firm Metrika has been given the green light to market in the US its point-of-care A1cNow INView multi-test system for monitoring levels of HbA1c, the current gold standard for diabetes control. Used in a doctor's office or at home, the pager-sized device provides laboratory-quality results in five minutes from a 10 microlitre finger prick sample. Doctors can then determine a patient's average blood sugar level over the previous 2-3 months, the Sunnyvale, California firm claims. Studies show that a 1% reduction in HbA1C can lower the risk of blindness, amputation, kidney and nerve disease by 40%. Metrika will introduce the system later this year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel